Technology | Neuro Imaging | March 15, 2018

FDA Clears CereMetrix’s Neuroimaging Analytics and Clinical Workflow Platform

CereMetrix Silver will feature advanced neuroimaging capabilities that automatically pinpoints and quantifies brain function down to the voxel level.

FDA Clears CereMetrix’s Neuroimaging Analytics and Clinical Workflow Platform

March 15, 2018 – CereMetrix, a subsidiary of CereHealth Corp., has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its neuroimaging analytics and quantification platform CereMetrix Silver. Providers will now have access to objective neuroimaging that detects, quantifies and analyzes brain function down to the voxel level.

The CereMetrix Silver image viewer is available to analyze brain imaging, including PET, SPECT, MRI and CT scans. The platform is designed to increase productivity and accuracy by providing reading physicians with significant workflow efficiencies, including automated cluster analysis that allows for quantitative and statistical analysis of SPECT brain scans by comparing to other registered SPECT brain scans. The proprietary workflow also features an automated reporting capabilities.

With CereMetrix Silver, reading physicians can now allow for the localization and definition of brain function and differentiate between hyper (more than average) and hypo (less than average) function in the brain. Within viewports, the reading doctor can process and display the brain image data in traditional two-dimensional formats, while simultaneously displaying pseudo three-dimensional renderings.

“With the current technology, functional brain imaging results are blended across entire anatomical areas, allowing far more subjectivity in the physician’s interpretation and findings,” said Shane Quint, Chief Technology Officer of CereScan. “CereMetrix Silver provides voxel-level measurements to help physicians objectively analyze the imaging, and make faster diagnostic decisions without compromising value-based care.”

CereMetrix Silver is to be used by trained medical professionals as a tool to aid in the evaluation and information management of digital medical images. The neuroimaging platform will also aid in the assessment of qSPECT (quantitative Single-Photon Emission Computed Tomography) brain scans. The brain imaging data, once reconstructed, will be mapped to a common brain template and anatomical map before applying a clustering algorithm to group pixels/voxels of tissue with deviations from average into clusters.

For more information: http://ceremetrix.io

Related Content

Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
News | Advanced Visualization | November 13, 2018
Canon Medical Systems USA and Applied Radiology will host a pair of expert-led forums in high-resolution imaging and...
MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
Deaconess Health System Chooses Sectra as Enterprise Imaging Vendor
News | Enterprise Imaging | November 02, 2018
International medical imaging information technology (IT) and cybersecurity company Sectra will install its enterprise...
Fans of Opposing Soccer Teams Perceive Games Differently

Image courtesy of University of York

News | Neuro Imaging | October 25, 2018
Scientists have scanned the brains of die-hard soccer fans to find out why supporters of rival teams often have very...
The OnSight 3D Extremity System captures weight-bearing 3D extremity exams.
Sponsored Content | Whitepapers | Advanced Visualization | October 24, 2018
The OnSight 3D Extremity System captures weight-bearing 3D extremity exams.
Enterprise imaging has been a hot topic in radiology and healthcare information technology (IT) circles for the last several years as medical image acquisition has moved beyond the exclusive purview of radiology.
Feature | Enterprise Imaging | October 03, 2018 | By Jeff Zagoudis
Enterprise imaging has been a hot topic in radiology and healthcare information technology (IT) circles for the last...
Brainlab and Magic Leap Partner in Digital Surgery
News | Advanced Visualization | September 28, 2018
September 28, 2018 — Brainlab announced a strategic development partnership with Florida-based Magic Leap, a develope
EOS Imaging Installs First Site in Mexico
News | Orthopedic Imaging | September 24, 2018
EOS imaging recently announced the first installation of an EOS system in Mexico, the largest Central American market,...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...